tetano
Editor, Senior Moderator
Cytokine
. 2023 Dec 20:174:156476.
doi: 10.1016/j.cyto.2023.156476. Online ahead of print. Protective effects of IL18-105G > A and IL18-137C > Ggenetic variants on severity of COVID-19
Mayara Tiemi Enokida Mori[SUP] 1 [/SUP], Andréa Name Colado Simão[SUP] 2 [/SUP], Tiago Danelli[SUP] 1 [/SUP], Sayonara Rangel Oliveira[SUP] 3 [/SUP], Pedro Luis Candido de Souza Cassela[SUP] 4 [/SUP], Guilherme Lerner Trigo[SUP] 1 [/SUP], Kauê Morais Cardoso[SUP] 5 [/SUP], Alexandre Mestre Tejo[SUP] 6 [/SUP], Zuleica Naomi Tano[SUP] 7 [/SUP], Elaine Regina Delicato de Almeida[SUP] 8 [/SUP], Edna Maria Vissoci Reiche[SUP] 9 [/SUP], Michael Maes[SUP] 10 [/SUP], Marcell Alysson Batisti Lozovoy[SUP] 8 [/SUP]
Affiliations
Objective and design: A cross-sectional study evaluated the IL18-105G > A (rs360717) and IL18-137C > G (rs187238) variants on Coronavírus Disease 2019 (COVID-19) severity.
Subjects and methods: 528 patients with COVID-19 classifed with mild (n = 157), moderate (n = 63) and critical (n = 308) disease were genotpyed for the IL18-105G > A and IL18-137C > G variants.
Results: We observed associations between severe + critical COVID-19 groups (reference group was mild COVID-19) and the IL18-105G > A (p = 0.008) and IL18-137C > G (p = 0.01) variants, which remained significant after adjusting for sex, ethnicity and age. Consequently, we have examined the associations between moderate + critical COVID-19 and the genotypes of both variants using different genetic models. The IL18-105G > A was associated with severe disease (moderate + critical), with effects of the GA genotype in the codominant [Odds ratio (OR), (95 % confidence interval) 0.55, 0.34-0.89, p = 0.015], overdominant (0.56, 0.35-0.89, p = 0.014) and dominant (0.60, 0.38-0.96, p = 0.031) models. IL18-105 GA coupled with age, chest computed tomograhy scan anormalities, body mass index, heart diseases, type 2 diabetes mellitus, hypertension, and inflammation may be used to predict the patients who develop severe disease with an accuracy of 84.3 % (sensitivity: 83.3 % and specificity: 86.5 %). Therefore, the presence of the IL18-105 A allele in homozygosis or heterozygosis conferred about 44.0 % of protection in the development of moderate and severe COVID-19. The IL18-137C > G variant was also associated with protective effects in the codominant (0.55, 0.34-0.89, p = 0.015), overdominant (0.57, 0.36-0.91, p = 0.018), and dominant models (0.59, 0.37-0.93, p = 0.025). Therefore, the IL18-137 G allele showed a protective effect against COVID-19 severity.
Conclusion: The IL18-105G > A and IL18-137C > Gvariants may contribute with protective effects for COVID-19 severity and the effects of IL18-137C > G may be modulating IL-18 production and Th1-mediated immune responses.
Keywords: Biomarkers; COVID-19; IL18; Inflammasome; Inflammation.
. 2023 Dec 20:174:156476.
doi: 10.1016/j.cyto.2023.156476. Online ahead of print. Protective effects of IL18-105G > A and IL18-137C > Ggenetic variants on severity of COVID-19
Mayara Tiemi Enokida Mori[SUP] 1 [/SUP], Andréa Name Colado Simão[SUP] 2 [/SUP], Tiago Danelli[SUP] 1 [/SUP], Sayonara Rangel Oliveira[SUP] 3 [/SUP], Pedro Luis Candido de Souza Cassela[SUP] 4 [/SUP], Guilherme Lerner Trigo[SUP] 1 [/SUP], Kauê Morais Cardoso[SUP] 5 [/SUP], Alexandre Mestre Tejo[SUP] 6 [/SUP], Zuleica Naomi Tano[SUP] 7 [/SUP], Elaine Regina Delicato de Almeida[SUP] 8 [/SUP], Edna Maria Vissoci Reiche[SUP] 9 [/SUP], Michael Maes[SUP] 10 [/SUP], Marcell Alysson Batisti Lozovoy[SUP] 8 [/SUP]
Affiliations
- PMID: 38128426
- DOI: 10.1016/j.cyto.2023.156476
Objective and design: A cross-sectional study evaluated the IL18-105G > A (rs360717) and IL18-137C > G (rs187238) variants on Coronavírus Disease 2019 (COVID-19) severity.
Subjects and methods: 528 patients with COVID-19 classifed with mild (n = 157), moderate (n = 63) and critical (n = 308) disease were genotpyed for the IL18-105G > A and IL18-137C > G variants.
Results: We observed associations between severe + critical COVID-19 groups (reference group was mild COVID-19) and the IL18-105G > A (p = 0.008) and IL18-137C > G (p = 0.01) variants, which remained significant after adjusting for sex, ethnicity and age. Consequently, we have examined the associations between moderate + critical COVID-19 and the genotypes of both variants using different genetic models. The IL18-105G > A was associated with severe disease (moderate + critical), with effects of the GA genotype in the codominant [Odds ratio (OR), (95 % confidence interval) 0.55, 0.34-0.89, p = 0.015], overdominant (0.56, 0.35-0.89, p = 0.014) and dominant (0.60, 0.38-0.96, p = 0.031) models. IL18-105 GA coupled with age, chest computed tomograhy scan anormalities, body mass index, heart diseases, type 2 diabetes mellitus, hypertension, and inflammation may be used to predict the patients who develop severe disease with an accuracy of 84.3 % (sensitivity: 83.3 % and specificity: 86.5 %). Therefore, the presence of the IL18-105 A allele in homozygosis or heterozygosis conferred about 44.0 % of protection in the development of moderate and severe COVID-19. The IL18-137C > G variant was also associated with protective effects in the codominant (0.55, 0.34-0.89, p = 0.015), overdominant (0.57, 0.36-0.91, p = 0.018), and dominant models (0.59, 0.37-0.93, p = 0.025). Therefore, the IL18-137 G allele showed a protective effect against COVID-19 severity.
Conclusion: The IL18-105G > A and IL18-137C > Gvariants may contribute with protective effects for COVID-19 severity and the effects of IL18-137C > G may be modulating IL-18 production and Th1-mediated immune responses.
Keywords: Biomarkers; COVID-19; IL18; Inflammasome; Inflammation.